Purchase Order 75N98026P00481

This $24,000 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Cellecta, Inc. Cellecta is a for-profit manufacturer of specialty genetic screening products and services used in medical research and drug discovery. The contract does not have a small business set-aside designation. Cellecta frequently partners as the prime contractor to provide CRISPR, RNAi, and other genomic...

This is a $96,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genetic research tools. The award supports NCATS' RNAi screening facility by enabling the development of flexible functional genomics platforms that offer complementary and orthogonal CRISPR screens to NIH intramural investigators. The contract does not...

This is a $14,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of advanced genetic screening technologies and services. The contract is for the delivery of a custom pooled CRISPR knockout library to support medical research and technology development initiatives. There is no set-aside designation for this award, and...

The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $24,512.25 firm fixed-price purchase order to Life Technologies Corporation of Carlsbad, California. As the prime contractor, Life Technologies will provide products or services to NIH NCATS between August 31 and October 1, 2023. The award is not associated with a multiple award contract vehicle. No subcontractors or set aside designations were indicated....

Editco Bio Inc., a small disadvantaged business specializing in advanced biomedical research services and cell line generation, was awarded a $14,857 firm fixed-price purchase order by the National Center for Advancing Translational Sciences (NCATS) on September 4, 2025. The contract calls for the delivery of a HIBIT-tagged FLT3 cell line to support scientific research, with performance in Redwood City, California and completion by September 3, 2026. This award carries no set-aside designation...

The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $16,000.00 firm fixed price purchase order to Cellecta, Inc. for the delivery of a "HUMAN GENOME-WIDE CRISPRI DUAL-SGRNA LIBRARY (VIRUS)". This order, which does not have a set-aside designation, will be completed by September 7, 2022. Cellecta, Inc. is a for-profit organization that specializes in providing genetic screening services, including...

The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), awarded a $23,940.00 firm-fixed-price purchase order to Life Technologies Corporation, a division of Thermo Fisher Scientific, for a View RNA in situ hybridization (ISH) cell assay kit. This acquisition supports NCATS' Cooperative Research and Development Agreement (CRADA) for Alagille syndrome (ALGS) research, specifically to screen compound libraries for activators of the...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $20,130.00 firm-fixed-price purchase order to Cellecta, Inc. (doing business as Cellecta Inc.), a for-profit organization and manufacturer of goods. The award is for the delivery of a human genome-wide CRISPR-Cas9 dual-single guide RNA (sgRNA) library (virus). This contract is not set aside for any type of small business. Cellecta has previously provided a...

This federal contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genomic research products and services. The $299,952 firm-fixed price contract is for "GENETIC ANALYSIS OF CTCS AT THE SINGLE-CELL LEVEL" and does not have a set-aside designation. Cellecta specializes in providing advanced genomic technologies, including CRISPR, RNAi, and other tools, to support biomedical research...

<p>The National Center for Advancing Translational Sciences (NCATS), a civilian agency, awarded a $35,000.00 firm fixed price purchase order contract to Editco Bio Inc., a self-certified small disadvantaged business. The contract, with an ultimate completion date of December 17, 2024, is for the product SYNTHEGO:1293873 [24-007185]. The contract does not have a set-aside designation.</p>